CDTX Cidara Therapeutics, Inc. Net earnings per share growth forecast for next year

Cidara Therapeutics Inc (CDTX) - corporate logo

Cidara Therapeutics (CDTX) is developing the Cloudbreak platform to combat influenza while integrating strict ESG standards and bioethics into its production. The history of earnings per share (EPS) expectation revisions demonstrates the market's reaction to these achievements, with the value stabilizing at 6.80. A stable defensive moat and strategic alliances with global behemoths effectively minimize the company's operational risks.

CDTX: Cidara Therapeutics Corp Expected earnings per share growth for next year 07/04/2022 - 01/17/2026

Analytical breakdowns for Cidara Therapeutics, Inc. (CDTX)

Basic company analysis:CDTX, Cidara Corp
Finished products of Cidara

The development of antiviral platforms and the success of Rezzayo determine the scaling potential of Cidara Therapeutics (CDTX). Analyzing the estimated annual EPS growth for the next period, investors can see a trend in consensus earnings forecasts that offsets reporting delays and reflects the market's actual confidence in the company's strategy; the growth of this indicator confirms the asset's fundamental stability and reduces the risk of overpaying for the shares.

Competitor analysis for Cidara Therapeutics

Expected earnings per share growth for next year GILD|Earnings growth forecast for next year novavax.com|Net earnings per share growth forecast for next year CureVac NV (CVAC)|Consensus forecast of earnings per share growth for next year Valneva Pharma|Earnings growth forecast for next year VIR (Vir Corp)|Consensus forecast of earnings per share growth for next year SIGA Corp (SIGA)|Emergent BioSolutions Inc - Earnings growth forecast for next year|Atea Pharmaceuticals - Projected earnings per share increase next year|IVVD (Invivyd Inc) - Expected earnings per share growth for next year|Enanta Pharmaceuticals Inc. (ENTA) - Earnings growth forecast for next year|INO (Inovio Pharma) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year HLVX|Net earnings per share growth forecast for next year Kalaris Therapeutics Inc (KLRS)|Consensus forecast of earnings per share growth for next year Dyadic International, Inc.|Earnings growth forecast for next year NNVC (nanoviricides.com)|Talphera Inc (TLPH) - Expected net earnings per share growth next year|COCP: Expected earnings per share growth for next year|Net earnings per share change forecast for next year TRAW|DWTX (Virios Therapeutics) - Expected earnings per share growth for next year|Projected earnings per share growth rate for next year QLGN|ALVR (AlloVir) - Earnings growth forecast for next year|vbivaccines.com (VBIV) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year VIRI|Expected earnings per share growth for next year Vaxart Corp VXRT